Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
Clinical Genitourinary Cancer
|
October 10, 2024
Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles
Anumita Chakraborty, Jill Hasler, Elizabeth Handorf, et al.
American Journal of Clinical Oncology
|
May 17, 2024
Multidisciplinary Educational Program to Standardize Education and Management of Immune-related Adverse Events: Review and Outcomes of a Single-institution Initiative
Matthew Zibelman, Victoria Wong, Jennifer Reilly, et al.
European Urology Oncology
|
July 6, 2022
Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy
Gregory Hemenway, Bianca Lewis, Pooja Ghatalia, et al.
European Urology
|
June 9, 2018
Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis
Shreyas S Joshi, Elizabeth A Handorf, Matthew Zibelman, et al.
European Urology Oncology
|
July 22, 2019
Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer
Shreyas S Joshi, Elizabeth R Handorf, Danielle Sienko, et al.
Clinical Genitourinary Cancer
|
December 3, 2014
A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite
Matthew Zibelman, Peter Barth, Elizabeth Handorf, et al.
Investigational New Drugs
|
June 21, 2015
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
Matthew Zibelman, Yu-Ning Wong, Karthik Devarajan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 4, 2025
Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma
Yasser Ged, Amina Touma, Luis Meza Contreras, et al.
The Oncologist
|
June 28, 2017
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
Julia Judd, Matthew Zibelman, Elizabeth Handorf, et al.
European Urology Oncology
|
March 3, 2023
Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon-degrading Bacteria Among Bladder Cancer Patients
Laura Bukavina, Ilaha Isali, Rashida Ginwala, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
Clinical Genitourinary Cancer
|
October 10, 2024
Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles
Anumita Chakraborty, Jill Hasler, Elizabeth Handorf, et al.
American Journal of Clinical Oncology
|
May 17, 2024
Multidisciplinary Educational Program to Standardize Education and Management of Immune-related Adverse Events: Review and Outcomes of a Single-institution Initiative
Matthew Zibelman, Victoria Wong, Jennifer Reilly, et al.
European Urology Oncology
|
July 6, 2022
Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy
Gregory Hemenway, Bianca Lewis, Pooja Ghatalia, et al.
European Urology
|
June 9, 2018
Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis
Shreyas S Joshi, Elizabeth A Handorf, Matthew Zibelman, et al.
European Urology Oncology
|
July 22, 2019
Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer
Shreyas S Joshi, Elizabeth R Handorf, Danielle Sienko, et al.
Clinical Genitourinary Cancer
|
December 3, 2014
A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite
Matthew Zibelman, Peter Barth, Elizabeth Handorf, et al.
Investigational New Drugs
|
June 21, 2015
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
Matthew Zibelman, Yu-Ning Wong, Karthik Devarajan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 4, 2025
Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma
Yasser Ged, Amina Touma, Luis Meza Contreras, et al.
The Oncologist
|
June 28, 2017
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
Julia Judd, Matthew Zibelman, Elizabeth Handorf, et al.
European Urology Oncology
|
March 3, 2023
Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon-degrading Bacteria Among Bladder Cancer Patients
Laura Bukavina, Ilaha Isali, Rashida Ginwala, et al.
Page
of 6